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poor rate of career progression, lack of benefits and financial 
support from institutions and the government. 
Although RTT does not perform certain activities in the 
clinic, the clinical domains described by ESTRO CC were 
classified by most RTTs as skills and competences acquired 
during the academic degree, but may not apply on their 
clinical daily practice. 
   
PD-0580   
Clinical evaluation of pitch and roll capabilities for patient 
setup in head and neck radiotherapy 
L. Woods1, C. Baker1 
1Clatterbridge Cancer Centre, Radiotherapy, Wirral, United 
Kingdom  
 
Purpose/Objective: To compare and quantify residual set-up 
errors for head and neck IMRT between 4DoF (translation and 
yaw) and 6DoF (translation plus pitch, roll and yaw) clinical 
accelerator couches and evaluate the impact on treatment 
time and imaging frequency. 
Materials and Methods: 30 retrospective patient records 
formed 2 groups of data for comparison. Group A (n=15) was 
treated on a traditional 4DoF Varian IGRT couch and group B 
(n=15) was treated on a Varian PerfectPitchTM 6DoF couch. 
293 CBCTs were analysed retrospectively. Each CBCT was 
registered at the superior, central and inferior level of the 
treatment volume. The differences in indicated 
displacements at each level relative to the online registered 
treatment position were recorded to indicate residual set-up 
error. Maximum shifts over the extent of the treatment 
volume in the vertical, longitudinal and lateral directions 
were averaged over the course of treatment along with their 
standard deviations. In addition, the maximum vector shift 
over the 3 registration levels was recorded for each fraction 
and averaged over the course of treatment. The time taken 
for image acquisition and analysis was recorded as were the 
number of repeat CBCTs performed. Significance testing for 
differences between groups was assessed via the t-test. 
Results: Improved setup accuracy for the 6DoF group was 
reflected through significantly smaller standard deviations of 
the maximum residual error in the vertical and longitudinal 
directions, as shown in the table below. Significantly reduced 
maximum vector shifts were also observed, from an average 
of 0.30 cm to 0.19 cm for the 4DoF and 6DoF groups 
respectively. Overall setup times for the 6DoF group were on 
average 2.4 minutes less than for the 4DoF group, as a result 
of a reduced number of repeat patient setups. 24 repeat 
CBCTs were required for the 4DoF group, due to an inability 
to correct for observed displacements, compared to 4 for the 
6DoF group. 
 
Conclusions: A significant reduction in the magnitude and 
variation of residual setup error and imaging time was 
observed when using a 6DoF robotic couch for head and neck 
IGRT. A maximum residual vector shift over the treatment 
volume of 0.19 cm for the 6DoF group is a significant 
improvement over the 0.3 cm achieved with the standard 
4DoF couch. Changes in neck flexion are common for this 
treatment site and whilst pitch rotation cannot always 
provide adequate correction, the number of repeat CBCTs 
required was found to be significantly reduced when this 
capability was available. From a resource perspective, 
significant time savings were observed when using a 6DoF 
couch. Using 15 minutes treatment slots as an example, the 
average saving of 2.4 minutes per patient found in this study 
could potentially allow 5 extra patients to be treated in an 
average 9 hour treatment day using a 6DoF couch. 
  
PD-0581  
In vivo dosimetry as verification of delivered dose leading 
to an adaptive radiotherapy 
G. Pastore1, C. Menichelli1, A. Fanelli1, S. Tubin1, C. 
Arrichiello1, S. Grespi1, A. Ferullo1, F. Casamassima1 
1Ecomedica, Radiotherapy Department, 50053, Italy  
 
Purpose/Objective: The control of VMAT plans is a key issue 
in the QA process. The steps in VMAT verification can be an 
independent calculation of monitor units, measurement of 
fluences or, using phantoms, measurement of point dose and 
dose distributions. This steps rely on phantoms to simulate 
the patient, with the consequent loss of realism in the 
verification. The possibility to evaluate the transit dose 
through the patient to calculate the 3D dose distribution in 
each fraction of treatment can detect some errors. 
Dosimetry Check (DC) (Math Resolutions, Columbia) is a 
commercial software for portal dosimetry which allows pre-
treatment verification and transit dose using transmitted 
fluence information gathered by the EPID. It overlaps isodose 
curves on the CT image, calculates the dose at reference 
points, reconstructs dose and gamma (Γ) volume histograms 
allowing possibility to verify the dose distribution to PTV and 
OAR and, if necessary, replanning it. 
In this study is tested the possibility to use the DC for an 
adaptive radiotherapy. 
Materials and Methods: 22 patients with prostate cancer, 6 
with head and neck and 18 with thoracic cancer were 
selected for this study. Dose calculation was performed using 
Monaco TPS (Elekta, Crawly). A VMAT plan was generated 
using a 6MV photon beam and Montecarlo optimization 
algorithm. Treatments were delivered through a MLC (4mm) 
Elekta SynergyS. Integrated images were acquired by EPID in 
continuous mode (60 frames/rotation) for the arc during the 
delivery and imported with planning CT data, associated 
structures and 3D dose matrix into DC. It uses the imported 
fluence fields to calculate the absolute dose and dose 
distribution through Pencil Beam (PB) algorithm. Analysis was 
based on the comparison between planned and delivered 
dose at isocenter (ΔD), and the calculation of Gamma Index 
(Γ). 
When a ΔD difference of 5% was found, or if there was a 
value of Γ index less than 95% for more than three days a re-
planning was considered. 
Results: Prostate cases: the ΔD is 4.9%(±4.1%). The mean Γ 
(3%;3mm) value is (95.3 ±2.3)%. In 5 cases, the Γ value is less 
than 95%, however Γ index for OARs and PTV is greater than 
95%. We deduced that the cold and hot spots were in the 
body. 
H&N cases: ΔD is 6.3%(±4.1%). Γ is 92.2%(±1.8%). In 3 cases 
the Γ is less than 90%: patients had lost weight, so it was 
necessary to re-planning it. 
Thoracic cancer: deviation ΔD is 6.5%(±4.8%). Γ passing rate 
test is 93.23%(±6.3%). Low values of Γ are due to the 
difference of the calculation algorithm between TPS and DC. 
Conclusions: DC seems to be a valid method for monitoring 
the delivering of a treatment planning and avoiding setup 
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errors, but is a need of incorporating a more accurate 
algorithm for patients in which low density regions are 
involved. In fact we note a discrepancy between measured 
and planned dose in thoracic cases. It is due to the DC Pencil 
beam algorithm of dose reconstruction, that over-estimates 
dose in heterogeneous area. 
 
Teaching Lecture: Organ sparing: A valid option in the 
treatment of bladder cancer  
 
 
SP-0582   
Organ sparing: A valid option in the treatment of bladder 
cancer  
O. Ott1 
1University Clinic Erlangen, Radiation Oncology, Erlangen, 
Germany  
 
In the framework of multimodality approaches combined 
radiochemotherapy for selected patients with bladder cancer 
already is accepted as alternative to radical cystectomy. 
Overall survival rates after five and ten years are 
comparable. The multimodality bladder preservation 
approach will be successful only in institutions with a close 
cooperation between urooncological and radiooncological 
partners. Combined radiochemotherapy is superior to 
radiation alone and therefore in a curative setting the use of 
simultaneous chemotherapy is mandatory. Further 
developments, e.g. brachytherapy, additional regional 
hyperthermia, the optimization of simultaneous 
chemotherapy, and the use of predictive biomarkers may 
further increase the results after organ-preserving 
multimodality treatment for patients with bladder cancer.  
  
 
Teaching Lecture: ESTRO: what’s in it for me?  
 
 
SP-0583   
ESTRO: What’s in it for me? 
P. Poortmans1 
1UMC St Radboud Nijmegen, Radiation Oncology, Nijmegen, 
The Netherlands 
   
 
Teaching Lecture: High throughput biological screens and 
their translation to new targets  
 
 
SP-0584   
High throughput biological screens and their translation to 
new targets 
W.G. McKenna1, R. Prevo1, R.J. Muschel1, T. Ashton1, G.S. 
Higgins1 
1Oxford Institute for Radiation Oncology University of 
Oxford, Oncology, Oxford, United Kingdom  
 
The therapeutic window of radiotherapy could be improved if 
tumor cells could be selectively rendered more sensitive to 
radiation. Such a strategy depends upon exploiting tumor 
specific targets, some of which, such as hypoxia in the 
microenvironment are well known, but many of which remain 
to be identified. The colony forming assay (CFA) is the ‘gold 
standard’ method for assessing intrinsic radiosensitivity in 
vitro. We have developed a technique to perform high-
throughput CFAs in 96 well plates and have recently 
completed siRNA screens of a selected DNA repair library and 
of approximately 10,000 additional genes, of which the 793 
gene ‘kinase’ section of the library has been examined in 
detail. The screens used a ranked-product analysis to identify 
the top hits. On the basis of the top candidate genes 
identified by the primary screen, a secondary library was 
then screened on multiple occasions. This work identified 
several genes such as ATM, ATR, DNA-PK and CHEK1, which 
are well known to play key roles in tumor cell 
radiosensitivity. In addition, we identified several novel 
genes whose depletion induced HeLa radiosensitisation in 6-
well plate CFAs. These experiments were repeated with 
separate siRNAs to ensure these findings were not the result 
of off-target effects. Depletion of these genes appeared to 
cause radiosensitisation in several other tumor cell lines as 
well. We are currently investigating the effects of several of 
these genes in greater detail. Ongoing work will be presented 
that clarifies the effects of gene knockdown on radio- in 
several tumor and normal tissue lines. The mechanism by 
which this knockdown causes these effects will also be 
presented for some of the targets. Tumor hypoxia is probably 
the major determinant of clinical outcome other than 
intrinsic radiosensitivity. Most work so far has concentrated 
on vascular effects in oxygen delivery as a determinant of 
this, but in fact oxygen consumption by the tumor cells is 
also a determinant of tumor oxygen concentration. We have 
developed screens for oxygen consumption. We used both the 
Pharmakon 1600 and Oncology drug set libraries for the 
screening. Our primary screen identified 100 compounds that 
reduced oxygen consumption (OCR) without significantly 
affecting cell death in FaDu hypopharyngeal cells. A 
secondary screen identified 50 compounds that reduced 
oxygen consumption (OCR) without significantly affecting cell 
death in either FaDu hypopharyngeal cells or MRC5 lung 
fibroblasts. The results of these “microenvironmental” 
screens will also be discussed.  
   
 
Teaching Lecture: Application of Monte Carlo methods in 
radiation treatment planning  
 
 
SP-0585   
Application of Monte Carlo methods in radiation treatment 
planning 
I. Chetty1 
1Henry Ford Health System, Radiation Oncology, Detroit, USA  
 
The availability of Monte Carlo (MC)-based codes optimized 
for photon and electron beams in patient-specific geometries 
has lead to the development of several different MC-based 
dose calculation systems for radiotherapy treatment 
planning. MC-based photon beam dose calculations today are 
performed within minutes in the routine clinical setting.  As 
MC-based planning systems become more widely utilized in 
the clinic, it is critical that paradigms and approaches for 
clinical commissioning and implementation of these systems 
be formulated and discussed.  This lecture will focus on such 
strategies in the context of MC calculations for external 
photon and electron beam radiotherapy.  The following 
topics will be covered: (a) Overview of the MC method for 
radiotherapy photon beam simulation; (b) Review of the 
methods used for characterization of the linear accelerator 
(linac) and patient simulation; (c) Techniques for 
commissioning and experimental verification of MC-based 
dose calculation systems, and associated challenges; (d) 
Tools for facilitating MC-based treatment planning in the 
clinical setting, e.g. methods for viewing of isodose plans 
with their combined statistical uncertainty distributions; (e) 
Issues specific to MC-based electron beam dose calculations.  
